Key result
Genetically proxied ACE inhibition equivalent to a 1-mm Hg reduction in systolic blood pressure was associated with an increased risk of colorectal cancer (OR 1.13; 95% CI 1.06-1.22; P=3.6×10-4).
Why the study?
Epidemiological studies have reported conflicting findings on the potential adverse effects of long-term antihypertensive medication use on cancer risk.
Does genetically proxied inhibition of antihypertensive drug targets affect the risk of common cancers?
Population
Individuals of European ancestry from GWAS consortia and the FinnGen consortium
Comparison
Genetically proxied inhibition of ACE, ADRB1, and NCC vs standard genetic levels
Design
Mendelian randomization analysis
Authors
Loading...
Should not alter ACE inhibitor prescribing; hypothesis-generating for a causal colorectal cancer link needing prospective validation.
Observational
Yes
Does genetically proxied inhibition of antihypertensive drug targets affect the risk of common cancers?
Odds Ratio: 1.13 (95% CI 1.06–1.22)
p-value: p=3.6 × 10-4
Genetically proxied long-term ACE inhibition is associated with an increased risk of colorectal cancer, suggesting a need for safety evaluation in clinical trials with adequate follow-up.
Yarmolinsky et al. (2022) conducted an observational in Common cancers (breast, colorectal, lung, and prostate). Genetically proxied inhibition of antihypertensive drug targets (ACE, ADRB1, and NCC) was evaluated on Risk of colorectal cancer (OR 1.13, 95% CI 1.06 to 1.22, p=3.6 × 10-4). Genetically proxied ACE inhibition equivalent to a 1-mm Hg reduction in systolic blood pressure was associated with an increased risk of colorectal cancer (OR 1.13; 95% CI 1.06-1.22; P=3.6×10-4).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: